retatrutide trial status The numbers from Lilly's Phase 3 dropped this week and I haven't been able to stop thinking about them. Not only as a doctor but as a long-term GLP-1 user Retatrutide - Wikipedia

GLP-1(936) inhibits glucagon secretion by activation of G i/o We hypothesised that the glucagonostatic effects of GLP-1(936) are mediated by activation of an inhibitory GTP-binding protein (G i/o )

Even if the FDA eventually approves it, theres no guarantee that the official retatrutide dosage will match the dosage used in the latest clinical trial

The children that participated in the study had appropriate suppression of insulin secretion in response to hypoglycemia and had a normal fasting tolerance, arguing against an underlying disorder of insulin secretion (39)

As a result, most GLP-1 therapies are delivered through subcutaneous injection, a small needle just under the skin